BACKGROUND: This case series summarizes our observations of hemolytic reactions after the administration of large amounts of intravenous immune (gamma) globulin (IVIG). STUDY DESIGN AND METHODS: Cases of hemolysis were identified by a decrease in hemoglobin not otherwise explained following IVIG administration. RESULTS: Sixteen cases were identified over a 2 1/2-year period at the Ottawa Hospital of approximately 1000 patients receiving IVIG (1.6%). Characteristics of these patients include a large dose of IVIG, female sex, non-O blood group, and underlying inflammatory state. CONCLUSIONS: Significant hemolysis may occur after the administration of large doses of IVIG. A two-step mechanism of hemolysis is proposed, sensitization by ABO isohemagglutinins followed by phagocytosis by activated macrophages. A simple protocol to facilitate the early detection of such cases is presented.
BACKGROUND: This case series summarizes our observations of hemolytic reactions after the administration of large amounts of intravenous immune (gamma) globulin (IVIG). STUDY DESIGN AND METHODS: Cases of hemolysis were identified by a decrease in hemoglobin not otherwise explained following IVIG administration. RESULTS: Sixteen cases were identified over a 2 1/2-year period at the Ottawa Hospital of approximately 1000 patients receiving IVIG (1.6%). Characteristics of these patients include a large dose of IVIG, female sex, non-O blood group, and underlying inflammatory state. CONCLUSIONS: Significant hemolysis may occur after the administration of large doses of IVIG. A two-step mechanism of hemolysis is proposed, sensitization by ABO isohemagglutinins followed by phagocytosis by activated macrophages. A simple protocol to facilitate the early detection of such cases is presented.
Authors: Jenny M Despotovic; Michele P Lambert; Jay H Herman; Terry B Gernsheimer; Keith R McCrae; Michael D Tarantino; James B Bussel Journal: Transfusion Date: 2011-10-07 Impact factor: 3.157
Authors: Melvin Berger; Paul J Pinciaro; Arthur Althaus; Mark Ballow; Akhilesh Chouksey; James Moy; Hans Ochs; Mark Stein Journal: J Clin Immunol Date: 2009-12-08 Impact factor: 8.317
Authors: Christine W Bruggeman; Sietse Q Nagelkerke; Wendy Lau; Cedric Manlhiot; Masja de Haas; Robin van Bruggen; Brian W McCrindle; Rae S M Yeung; Taco W Kuijpers Journal: Blood Adv Date: 2020-07-28
Authors: Joseph Kahwaji; Eva Barker; Sam Pepkowitz; Ellen Klapper; Rafael Villicana; Alice Peng; Robert Chang; Stanley C Jordan; Ashley A Vo Journal: Clin J Am Soc Nephrol Date: 2009-10-15 Impact factor: 8.237